New hope for Hard-to-Treat lung cancer: targeted drug combo enters human trials
NCT ID NCT05482568
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two new drug combinations for people with advanced non-small cell lung cancer that has a HER2 mutation. The drugs are SHR-A1811 (given by IV) combined with either pyrotinib (a pill) or SHR-1316 (another IV drug). The trial has two parts: first, finding the safest dose, and second, seeing how well the combination works. About 324 participants are being recruited at multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1811 (a targeted drug) combined with either pyrotinib (oral) or SHR-1316 (intravenous)
What this could lead to
If successful, this could provide a new treatment option for people with advanced HER2-positive lung cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the benefits and risks are not yet proven. Side effects from the drug combinations are possible and will be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact